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Abstract
A better understanding of human NK cell development in vivo is crucial to exploit NK cells for immunotherapy. Here, we
identified seven distinctive NK cell developmental stages in bone marrow of single donors using 10-color flow cytometry
and found that NK cell development is accompanied by early expression of stimulatory co-receptor CD244 in vivo. Further
analysis of cord blood (CB), peripheral blood (PB), inguinal lymph node (inLN), liver lymph node (liLN) and spleen (SPL)
samples showed diverse distributions of the NK cell developmental stages. In addition, distinctive expression profiles of
early development marker CD33 and C-type lectin receptor NKG2A between the tissues, suggest that differential NK cell
differentiation may take place at different anatomical locations. Differential expression of NKG2A and stimulatory receptors
(e.g. NCR, NKG2D) within the different subsets of committed NK cells demonstrated the heterogeneity of the
CD56
brightCD16
+/2 and CD56
dimCD16
+ subsets within the different compartments and suggests that microenvironment
may play a role in differential in situ development of the NK cell receptor repertoire of committed NK cells. Overall,
differential in situ NK cell development and trafficking towards multiple tissues may give rise to a broad spectrum of mature
NK cell subsets found within the human body.
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Introduction
Natural killer (NK) cells are large CD56
+CD3
2 granular
lymphocytes and are considered part of the innate immune
system. NK cells can kill infected or malignant transformed cells
without prior sensitization, and through the production of
cytokines, such as IFN-c, they form a bridge between innate and
adaptive immune responses [1,2]. NK cell reactivity is tightly
regulated through a balance of signals between stimulatory and
inhibitory receptors, a feature that is being exploited today for NK
cell-based immunotherapy against cancer [3]. For this, a thorough
understanding of human NK cell development in vivo is crucial.
Bone marrow (BM) is generally considered as the primary site
for human NK cell development [4–7]. However, a complete
pathway for NK cell development and maturation in BM has not
been described and it may be possible that precursor NK cells
traffic from BM to other tissues for terminal differentiation in situ
[8]. In 2005, Freud et al. [9] identified a BM-derived CD34
+
hematopoietic precursor cell residing in lymph nodes (LN) where
further differentiation into CD56
bright cells could take place.
Subsequently, they identified four discrete stages for human NK
cell development within secondary lymphoid tissues (SLT) based
on cell surface expression of CD34, CD117 and CD94: stage 1,
CD34
+CD117
2CD94
2; stage 2, CD34
+CD117
+CD94
2; stage 3,
CD34
2CD117
+CD94
2; and stage 4, CD34
2CD117
+/2CD94
+
[10]. Following NK cell development, commitment to the NK cell
lineage takes place at stage 3, in which CD56 appears on the cell
surface and gives rise to CD56
bright NK cells in stage 4. These data
confirmed previous research describing the abundant presence of
CD56
bright NK cells in SLT [11,12]. In addition, we and others
have shown that CD56
bright cells are the first mature NK cells to
arise after allogeneic stem cell transplantation (SCT) [13,14].
Overall, these data support a model of in vivo human NK cell
development in which CD34
+ NK cell precursors may traffic from
BM to SLT where further differentiation into CD56
bright NK cells
occurs. However, how these NK cell developmental stages
correlate with NK cell subsets in other compartments of the
human body (e.g. peripheral blood (PB), spleen (SPL)) remains
unclear.
In this study, we identified seven distinctive NK cell develop-
mental stages in bone marrow using 10-color flow cytometry and
found that NK cell development is accompanied by early
expression of stimulatory co-receptor CD244 in vivo. Furthermore,
distinctive expression profiles of early development marker CD33
and the C-type lectin receptor NKG2A between different tissues,
suggest that differential in situ NK cell differentiation may take
place at different anatomical sites. Thus, differential in situ NK cell
development and potential trafficking towards multiple tissues may
give rise to a broad spectrum of mature NK cell subsets found
within the human body. The findings presented here may serve as
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e30930a fundamental basis for ongoing and future NK cell development
studies and the development of NK cell generation protocols used
for clinical purposes.
Results
To identify human NK cell developmental stages within the
different tissues and to analyze the distribution of different NK cell
subsets and their NK cell receptor repertoire, we designed three
10-color flow cytometry (FCM) panels (Table 1). As BM is
considered the origin of NK cell development [4–7], we first
analyzed BM for the presence of NK cell developmental stages.
Identification of seven NK cell developmental stages in
BM
Distinct NK cell developmental stages can be characterized
through expression analysis of CD34, CD117, CD94 and CD56
antigens [10]. Based on that, we gated our samples on the
CD45
+CD3
2 population within CD45
+/SS gated cells to exclude
T cells and endothelial cells from analysis. Subsequently, cell
subsets were first divided based on the expression of CD34 and
CD117. From there, in a second step, each subset was analyzed for
CD56 and CD94 expression. Using this gating strategy, we were
able to identify seven distinctive developmental stages in BM
(Fig. 1).
On this basis and in concert with NK cell developmental stages as
identified in SLT [10], we now propose the following model of NK
development (Table 2), starting from multi-potent CD34
+
CD117
2CD56
2CD94
2 cells (stage 1), followed by the gain of
CD117 (stage 2; CD34
+CD117
+CD56
2CD94
2). Subsequently,
CD34 expression is lost in stage 3a (CD34
2CD117
+CD56
2CD94
2)
followed bylossofmulti-potencyandacquirement ofNKcelllineage
commitment through CD56 acquisition in stage 3b (CD34
2
CD117
+CD56
+CD94
2). After NK cell lineage commitment, cells
gain CD94 expression and develop into immature CD56
bright NK
cells (stage 4; CD34
2CD117
+CD56
+CD94
+). Through loss of
CD117 expression, CD56
dim cells start to develop (stage 5a;
CD34
2CD117
2CD56
+CD94
+), followed by loss of CD94 expres-
sion in stage 5b (CD34
2CD117
2CD56
+CD94
2). It should be
noted, however, that stage 1 and stage 2 cells still obtain multi-
lineage potential and therefore not only contain NK cell precursors
but can also give rise to other cell lineages (e.g. T cells, DCs) [10].
Early and sustained CD244 expression following in vivo
NK cell developmental stages
By using 10-color FCM, we were able to further specify the
identified NK cell developmental stages in BM by analyzing
additional antigen expression. For this purpose, we analyzed the cell
surface expression of CD133, CD33, CD244 and NKG2A within
each defined stage (Fig. 2). CD133 is known as a stem cell antigen
w h i c hi se x p r e s s e de a r l i e ri nm a t u r a t i o nt h a nC D 3 4a n d ,a ss u c h ,
may provide an alternative to CD34 for the selection and expansion
of hematopoietic cells for transplantation [15]. Together with CD34,
this antigen was only expressed within stages 1 and 2. CD33 has been
described as an antigen for early NK cell development when showing
lower fluorescence intensity as compared with its expression on
myeloid cells [16] and was expressed in stages 2 and 3a. The CD244
receptor is suggested to be a co-receptor in activation of mature NK
cells [17]. Interestingly, we found that CD244 was already expressed
on CD34
+CD117
+ stage 2 cells in BM. During stages 3a and 3b,
CD244 expression remained present and the amount of CD244
+cells
was increased to more than 98% in stages 4 to 5b. Until now, CD244
expression was only shown to be present at early stages of human NK
cell differentiation during ex vivo induced human NK cell maturation
[18].Recently, however, Fathman etal. showedthat the expressionof
CD244 is linked to NK cell lineage commitment in an in vivo mouse
model [19]. Thus, this suggests that NK cell lineage commitment
may already be induced in part of early stage 2 and 3 cells, and that
CD244 could be an important marker to dissect NK lineage
committed cells from other lineage committed cells. The inhibitory
NKG2A receptor, shown to be expressed early during NK cell
maturation [13], was detected starting from stage 4 just after NK cell
commitment (stage 3b) till stage 5b. In summary, as the different
assessed antigens showed distinct expression profiles within the
different stages, we were able to further refine the developmental
stages as shown in Table 2 (Table 3), in which CD133 expression is
e x p r e s s e dw i t h i ns t a g e s1a n d2 ,f o l l o w e db yC D 3 3e x p r e s s i o ni n
stages 2 and 3. In stage 2 and 3a, CD244 is upregulated followed by a
continuous expression from stage 3b to 5b, and NKG2A is found in
stages 4 to 5b on part of the cells.
NK cell development starts in BM, followed by further
maturation in LN, SPL and PB
To assess whether the NK developmental stages can be found in
other human tissues besides BM, we further analyzed samples of
Table 1. Panels used for flow cytometry.
FITC PE ECD PC5.5 PC7 APC APC-A700 APC-A750 PB PO
1 CD34 CD133 CD3 CD159a CD117 CD33 CD244 CD56 CD94 CD45
581 AC133 UCHT1 Z199.1.10 104D2D1 D3HL60.251 C1.7.1 N901 HP-3B1 J33
2 CD16 CD159c CD3 - CD158b CD158e1 CD158a CD56 CD159a CD45
DJ130c 134522 UCHT1 - GL183 Z27.3.7 EB6.B.3.1.1 N901 Z199.1.10 J33
3 CD16 CD336 CD3 CD337 CD335 CD314 CD244 CD56 - CD45
DJ130c Z231 UCHT1 Z25 BAB281 ON72 C1.7.1 N901 - J33
Displayed are the combinations of conjugated monoclonal antibodies (mAb) against specific antigens within each panel. In addition, the clone for each specific mAb is
shown. Each panel was used for flow cytometric (FCM) analysis of bone marrow, cord blood, peripheral blood, inguinal LN, liver LN, and spleen samples of human
donors (all n=5). Thawed MNC fractions of the human tissue samples were assessed on a NaviosTM 10-color flow cytometer and analyzed using Kaluza SoftwareH 1.0
(Beckman coulter). Panel 1 was used to identify different NK cell developmental stages based on CD34, CD117, CD94 and CD56 expression profiles.
10 Additionally,
expression of early development markers CD133 and CD33, stimulatory co-receptor 2B4 (CD244), and C-type lectin NKG2A were analyzed to refine the definition of the
different NK cell developmental stages. Panel 2 and 3 were used to analyze the NK cell receptor repertoire of CD45
+CD56
brightCD16
+/2CD3
2 and
CD45
+CD56
dimCD16
+CD3
2 NK cells consisting of inhibitory and stimulatory receptors. Inhibitory receptors contain KIR (CD158a, CD158b, CD158e1) and NKG2A
(CD159a). Stimulatory receptors contain NCR (CD335/336/337), NKG2C (CD159c), NKG2D (CD314), and 2B4 (CD244).
doi:10.1371/journal.pone.0030930.t001
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LN (liLN) and spleen (SPL) (Fig. 3). Results showed a differential
distribution of the NK cell developmental stages within the
different tissues. The NK cell developmental stages in BM mainly
consisted of stage 5a and 5b cells. In addition, stages 1 and 2 were
only detected in BM, confirming BM as the origin of NK cell
development. In CB, stage 2 cells were found, but not in PB,
suggesting that blood of fetal origin may possibly contain more
early NK progenitor cells as compared with adult blood. However,
the main NK cell developmental stages in CB and PB were stage
5a and 5b cells. In contrast to other tissues, the distribution of NK
cell developmental stages in inLN primarily contained stage 3a
and stage 3b cells, and showed lower, but similar, frequencies of
stages 4 to 5b. In contrast, NK cell developmental stages in liLN
and SPL consisted primarily of stages 4, 5a and 5b cells.
To exclude that stage 3a and 3b consisted largely, not of
potential precursor NK cells, but rather of lymphoid tissue inducer
cells (LTIs; RORct
+NKp44
+CD127
+) [20], we additionally
stained two inLN and liLN samples for stage 3 markers combined
with RORct, NKp44 and CD127 mAbs. Results showed that
stage 3a in inLN and liLN contained only 0.8–15% and 3.9–4.8%
LTIs, respectively. Stage 3b in inLN and liLN contained 7–21%
and 13–19% LTIs, respectively (data not shown). This suggests
that stage 3a and 3b in the lymphoid compartments may primarily
consist of precursor NK cells.
Following the presence of the different NK developmental
stages within the different tissues analyzed, our results suggest that
early NK progenitor cells may potentially migrate from BM to
SLT, after which pre-NK cells (stage 3a) may further develop in
LN leadings to NK cell commitment (stage 3b), followed by further
maturation in splenic tissue and the release of mature NK cells
into the blood stream. The presence of different stages within one
tissue, for instance stages other than stage 1 and 2 in BM or stage 3
in LN, suggests that in situ differentiation of remaining cells may
also occur besides potential trafficking of developmental stages
towards other tissues.
Figure 1. Identification of seven NK cell developmental stages in bone marrow (BM). Based on the stages defined in Table 1, we analyzed
the presence of the different NK cell developmental stages in BM. Shown is one representative example (n=5). Cells were gated on the CD45
+CD3
2
population within CD45
+/SS gated cells to exclude T cells and endothelial cells from analysis. Subsequently, cell subsets were divided based on the
expression of CD34 and CD117. From there, each subset was analyzed for CD56 and CD94 expression, leading to the identification of seven NK cell
developmental stages: 1, 2, 3a, 3b, 4, 5a, 5b.
doi:10.1371/journal.pone.0030930.g001
Table 2. Developmental stages of NK cells in BM.
CD34 CD117 CD56 CD94
CD56: bright or
dim
Stage 1 + 22 2 -
Stage 2 ++ 22-
Stage 3a 2 + 22-
Stage 3b 2 ++ 2 CD56
dim
Stage 4 2 ++ + CD56
bright
Stage 5a 22 ++CD56
bright,dim
Stage 5b 22 + 2 CD56
bright,,dim
Main stages of NK cell development in BM based on expression profiles of
CD34, CD117, CD56 and CD94 using flow cytometry panel 1 (Table 1).
doi:10.1371/journal.pone.0030930.t002
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cell developmental stages
To assess potential differences of the NK cell developmental
stages within the human tissues, we further analyzed the
expression of CD133, CD33, CD244 and NKG2A within the
stages present in the human tissues (Fig. 4). Between BM and CB,
there were no significant differences in expression of CD133,
CD33 and CD244 within stage 2. The subsequent trend of CD244
acquisition was comparable for each tissue and all tissues showed
more than 98% CD244
+ cells in stages 4 and 5a/b. Significant
differences were seen in the expression profile of the early CD33
antigen within the different human tissues. As we previously
characterized CD33 expression to be specific for stage 2 and 3a
cells in BM (Table 3), CD33 expression was prolonged in CB, PB,
and SPL until stage 3b. Furthermore, in liLN, CD33 expression
was even sustained after NK cell commitment until stage 4. The
prolonged expression of CD33 in some distinct stages and tissues
may be due to tissue specific NK cell developmental subsets in situ.
NKG2A expression reveals an impaired NK cell
maturation profile in lymphoid tissues
Following the evaluation of the tissue specific NK cell subsets,
by the expression profile of CD33, we subsequently studied
whether the tissue specific differences are also expressed in the NK
cell maturation pattern. As the level of NKG2A expression may be
representative for the level of NK cell maturation [21,22], we
analyzed the NKG2A expression profile on ‘‘committed’’ NK
cells. Besides the significant differences in the CD33 expression
profile, the expression profile of NKG2A also showed a distinction
between the different human tissues. In stage 4, all tissues
contained more than 95% NKG2A
+ cells. Following NK cell
developmental stages, BM, CB and PB showed a decrease in the
percentage of NKG2A
+ cells up to approximately 25% in stage 5b,
whereas in both LN a median of 75–80% remained NKG2A
+ and
SPL kept a median of 50% NKG2A
+ cells. The stronger decrease
of NKG2A
+ cells in BM, CB and PB as compared with other
tissues was also reflected in the mean fluorescence intensity (MFI)
of NKG2A expression following stage 4 to 5b (Fig. S1). Overall,
these data suggest that the committed NK cells in LN and SPL
have a more immature phenotype as compared with cells present
in BM, PB and CB.
In order to better define NK cell maturation, we extended our
analyses with regard to ‘‘committed’’ NK cells. Therefore, we
subsequently analyzed the expression of additional NK cell
receptors to further asses the maturity status of the committed
NK cells within the different human tissues.
Differences in the NK cell receptor repertoire suggest
distinct in situ NK cell development within LN and CB
Phenotypically committed NK cells (CD45
+CD3
2CD56
+) can
generally be divided into two distinguishable subsets: the
CD56
brightCD16
+/2 and the CD56
dimCD16
+ subset [23]. Our
data confirmed the heterogeneity of the CD56
brightCD16
+/2 and
CD56
dimCD16
+ subsets within BM, CB, PB, and LN, showing
balances of CD56
bright..CD56
dim in LN, and CD56
bright
,,CD56
dim in BM, CB and PB (Fig. S2). Additionally, we
identified a CD56
bright<CD56
dim balance in SPL.
To further assess the maturity of the committed NK cell subsets,
we analyzed the expression of killer immunoglobulin-like receptors
(KIR), NKG2A/C, NKG2D, CD244 and natural cytotoxicity
receptors (NCR; NKp30, NKp44, NKp46) within the CD45
+
CD56
+CD3
2 population by using FCM panels 2 and 3 (Table 1).
These receptors trigger and modulate mature NK cell effector
function through a balance between inhibitory (KIR, NKG2A)
and stimulatory signals (NKG2C, NKG2D, CD244, NCR) [2,24].
We first analyzed the NK cell receptor repertoire of the
CD56
brightCD16
+/2 subset within the committed NK cell
population of each tissue (Fig. 5). Results showed that there was
no difference in the amount of KIR
+ cells between the tissues.
Nevertheless, the MFI of KIR2DL/S2/3 and KIR3DL1 was
lower in both LN and SPL, suggesting a more immature
phenotype of CD56
bright cells as compared with BM, CB and
Figure 2. Expression of CD133, CD33, CD244 and NKG2A
within the NK cell developmental stages in bone marrow (BM)
(n=5). Left panels show the percentages of cells positive for the
specific markers. Right panels show the mean fluorescence (MFI) of
each specific marker.
doi:10.1371/journal.pone.0030930.g002
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+ cells was significantly
lower in liLN as compared to other tissues. This may be explained
by a different NK cell development in situ, as suggested by the
prolonged expression of CD33 (Fig. 4). Furthermore, the amount
of activating receptor positive cells, with the exception of NKp44,
was also lower in liLN as compared with other tissues. This was
also reflected within the CD56
dimCD16
+ subset of liLN, showing
lower amounts of NKG2D
+, CD244
+ and NKp30
+ cells as
compared with other tissues (Fig. 6). Thus, these results suggest
that NK cell development in LN may differ in situ between LN at
different anatomical locations and also other tissues.
Analysis of CB showed that both the CD56
brightCD16
+/2 (Fig. 5)
and the CD56
dimCD16
+ (Fig. 6) subset contained significantly
more NKG2A
+ cells as compared with other tissues. In addition,
the level of NKG2A expression (MFI) in the CD56
brightCD16
+/2
subset was also significantly higher, which confirmed previous
results [25]. NKG2C, which is the stimulatory lectin-like
counterpart of NKG2A, also showed elevated expression within
the CD56
brightCD16
+/2 subset of committed NK cells in CB
(Fig. 5). These data suggest that the fetal micro-environment of CB
may provide prevalence for the expression of lectin-like antigens as
compared with other human tissues.
Overall, the data on the NK cell receptor repertoire within the
different subsets of the committed NK cells demonstrates the
heterogeneity of the CD56
brightCD16
+/2 and CD56
dimCD16
+
within the different compartments and suggests that microenvi-
ronment may play a role in differential in situ development of the
NK cell receptor repertoire of committed NK cells.
Discussion
In contrast to T and B cells, the developmental pathways and
locations for human NK cell development are currently less well
defined. Results of this study suggest that this is partly due to the
heterogeneity of NK cell subsets and their diverse anatomical
distribution over the different compartments within the human
body. Using 10-color FCM, we were able to distinguish seven NK
cell developmental stages, which are numbered in line with the
initial 4 stages as described by Freud et al. [10] and that we further
specified by the expression profiles of CD133, CD33, CD244 and
NKG2A. It should be noted, however, that of the seven stages that
we detected, stages 1 and 2 still obtain multi-lineage potential,
whereas NK cell lineage commitment is described to be completed
in stage 3 [10]. Our results showed that NK cell development may
be accompanied by early expression of CD244 starting at stage 2–
3 and that there is a diverse distribution of the NK cell
developmental stages among different human tissues. In addition,
we provided a detailed phenotypical characterization of the
committed NK cell population revealing different NK cell
maturation stages (i.e. CD56
bright:CD56
dim ratio and heterogene-
ity in the NK cell receptor repertoire) within the tissues.
Our data pointed that NK cell development originates from BM
as stage 1 and 2 cells (CD34
+CD117
2CD56
2CD94
2 and
CD34
+CD117
+CD56
2CD94
2, respectively) were only found in
BM and not in LN, SPL or PB. This is in contrast to the findings of
by Freud et al., who identified stage 1 and 2 cells in SLT [10]. This
may be due to differences in sample preparation before analysis. In
the previous study, for each donor tissue, cells from multiple tonsil
pieces or multiple LN were pooled in order to obtain sufficient
numbers within each NK cell developmental stage. In contrast,
with the use of 10-color flow cytometry, we were able to study
small sample sizes of tissues obtained from single donors. Due to
biological variation between donors, pooled samples of each tissue
may cause a non-representative view on NK cell subset numbers
present within the different tissues analyzed. However, due to the
detection limits that we set for our analysis, we cannot rule out that
very small populations remained undetected within our samples.
Nevertheless, without pooling samples, we believe that this unique
collection of tissue samples provides a genuine view on the
distribution of the different NK cell developmental stages within
the different anatomical locations as they are in vivo.
Upon acquiring CD56 expression (NK cell commitment), the
cells acquired CD94 expression. Simultaneously, NKG2A positive
cells appeared. Later, following NK cell development, CD94
expression decreased during the final maturation steps towards a
CD56
dim phenotype together with a decrease in NKG2A
expression [16,26]. This phenomenon has also been described in
the setting of allogeneic SCT. Following NK cell repopulation
after allogeneic SCT, we and others have shown that CD56
bright
cells are the first committed NK cells to arise in the early phase
after transplantation followed by the repopulation of CD56
dim cells
suggesting a CD56
bright to CD56
dim developmental pathway
[13,14]. This has been further supported by research of Dulphy
et al. in which an intermediate CD56
brightCD16
low population was
found in the early phase after allogeneic SCT before repopulation
of the CD56
dimCD16
+ subset [27]. Overall, our findings described
in this paper are in line with the in vivo repopulation of NK cells
after allogeneic SCT and therefore support a model in which
CD56
bright cells further develop into CD56
dim cells which may
ultimately result in the CD56
bright,,CD56
dim ratio as seen in the
periphery of healthy individuals. The concomitant downregulation
of NKG2A with CD94 during the final maturation steps towards a
Table 3. Developmental stages of NK cells in BM (continued).
CD133 CD34 CD33 CD117 CD244 CD56 CD94 NKG2A CD56: bright or dim
Stage 1 +/2 + 22 2 22 2 2 2 -
Stage 2 ++ + +/2 + +/22 2 2 2 -
Stage 3a 22 2 +/2 + +/22 2 2 2 -
Stage 3b 22 2 2 + ++ + 2 2 CD56
dim
Stage 4 22 2 2 + ++ + + + CD56
bright
Stage 5a 22 2 22 2 ++ + + +/2 CD56
bright,dim
Stage 5b 22 2 22 2 ++ + 2 +/2 CD56
bright,,dim
Further identification of developmental NK cell stages in BM based on expression of CD133, CD34, CD33, CD177, CD244, NKG2A, CD56 and CD94 using flow cytometry
panel 1 (Table 1). Indicated is the presence of each specified marker within each stage (based on the percentage of positive cells present): +=100–80%; +/2,80%;
2=below reliable detection limits.
doi:10.1371/journal.pone.0030930.t003
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dim phenotype may be explained by the fact that these two
molecules form a functional inhibitory NKG2A/CD94 heterodi-
mer recognizing the ubiquitously expressed HLA-E molecule
[28,29]. Notably, we also observed a mature in vivo NK cell
developmental stage, that primarily consisted of CD56
dim cells,
expressing low levels of NKG2A without CD94 (stage 5b). The
low expression level of NKG2A in combination with the fact that
NKG2A only contributes to the binding affinity of the heterodi-
meric complex and HLA-E solely interacts with CD94 [29],
suggests that in this case NKG2A is non-functional. Recently, the
functional NKG2A/CD94 receptor complex was described to be
endocytosed by a macropinocytic-like process, which may be
related to the maintenance of its surface expression [30]. However,
as it is not clear whether the NKG2A/CD94 complex is
internalized as a whole or may be first uncoupled before
internalization, it may be possible that for a brief period NKG2A
may exist on the cell surface without CD94. Together, this
suggests that inhibition of cells in stage 5b largely depends on KIR
signaling, and that stage 5b is one of the final stages in NK cell
development.
Remarkably, the phenotype of committed NK cells (stage 3b-
5b) differed between both LN (liver and inguinal sites). The NK
cell receptor repertoire in liLN showed significantly less cells
expressing NKG2A/C, NKp30, CD244 and NKG2D. All
together, these results suggest that committed NK cells in liLN
reside in an even more immature state as compared with
committed NK cells in inLN. This was confirmed by the
expression of CD33, a marker for early NK cell development,
which is expressed significantly longer by committed NK cells in
liLN as compared with inLN and other tissues following NK cell
development. Similarly, CD56
bright NK cells in the liver itself show
a more immature phenotype as compared to their counterpart in
PB [31]. The differences in NK cell differentiation in situ after NK
cell commitment may be due to the regional immune system of the
liver, which is characterized by relatively weak cellular immune
responses and hyporesponsiveness to antigens and bacterial
product derived from the intestines [32]. As NK cells form a
bridge between innate and adaptive immune responses, the
immature state of committed NK cells in liver and its draining
LN may play a role in this. However, as we were not able to
perform functional analysis due to small sample sizes, this remains
subjected to further study.
Our findings confirm results from previous studies showing that
the CD56
brightCD16
+/2 and CD56
dimCD16
+ subsets are present
in the same proportions in both CB and PB [33,34]. Nevertheless,
these studies also reported that CB NK cells have a natural
reduced killing ability as compared with PB NK cells. We
postulate that this may be due to differences in NKG2A expression
as our results showed that NKG2A is significantly more expressed
in CB as compared with PB and also other tissues. Nevertheless,
the reduced killing ability of CB NK cells can be reversed after
cytokine stimulation [33,34]. Thus, as CB is a source for ex vivo
generation of NK cell-based immunotherapeutics [35], the high
expression of NKG2A and its inhibitory effect on CB NK cell
function may not necessarily form a problem for NK cell-based
immunotherapeutic strategies.
Although our analysis of the committed NK cells could not
distinguish NK cell subsets between stages 3b to 5b, the ratio
between the CD56
brightCD16
+/2 and CD56
dimCD16
+ subsets and
the overall expression of KIR and NKG2A provided a clear
overview on the maturation status of committed NK cells within
the different tissues. Committed NK cells in LN represented the
most immature status as the NK cells profoundly consisted of
CD56
brightCD16
+/2 cells, followed by SPL showing an equal
balance of both subsets. BM, CB and PB held the most mature
status of NK cells as they abundantly contained the
CD56
dimCD16
+ subset. After allogeneic SCT, in vivo maturation
of the NK cell receptor repertoire is characterized by fast
upregulation of NKG2A followed by the acquisition of KIR
together with a slow decrease in NKG2A expression
Figure 3. Distribution of the NK cell developmental stages in
different human tissues. Shown are the results for bone marrow
(BM), cord blood (CB), peripheral blood (PB), inguinal LN (inLN), liver LN
(liLN) and spleen (SPL) (all n=5). Shown are all NK cell developmental
stages within each tissue; *P,.05, **P,.01, ***P,.0001.
doi:10.1371/journal.pone.0030930.g003
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within the different tissues analyzed confirm these findings as the
overall KIR expression was highest in BM, CB and PB, followed
by SPL and was lowest in LN. With the exception of CB, ranges of
NKG2A expression were lowest in BM and PB, followed by a
higher range of NKG2A expression in LN and SPL.
In summary, these data may support a model for in vivo NK cell
development indicating BM as the origin of NK cell development
(Fig. 7). Through trafficking of precursor NK cells from BM to LN,
commitment to the NK cell lineage may take place in LN followed
by potential in situ differentiation and restricted maturation of the
NK cell receptor repertoire. For further differentiation of
committed NK cells, stage 3b CD56
dim cells or stage 4 CD56
bright
cells may traffic towards splenic tissue in which stage 5 cells could
develop and further maturation of the NK cell receptor repertoire
can take place. Final maturation of NK cells may occur through
trafficking of cells (stage 4 to 5) towards the periphery from which
NK cells may be further distributed to different compartments in
the human body. Although the phenotypical data presented in this
paper are of course no direct evidence for the proposed model, this
is the first study in which the presence of different NK cell
developmental stages and their mature subsets are analyzed within
a unique set of healthy human tissue samples in great detail.
Therefore, our results may serve as a valuable and important basis
Figure 4. Expression of CD133, CD33, CD244 and NKG2A within the NK cell developmental stages. Shown are the results for bone
marrow (BM), cord blood (CB), peripheral blood (PB), inguinal LN (inLN), liver LN (liLN) and spleen (SPL) (all n=5); *P,.05, **P,.01, ***P,.0001.
doi:10.1371/journal.pone.0030930.g004
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PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e30930Figure 5. Expression of KIR, NKG2A/C, NCR, NKG2D and CD244 within the CD56
brightCD16
+/2 NK cell subset of committed NK cells
in bone marrow (BM), cord blood (CB), peripheral blood (PB), inguinal LN (inLN), liver LN (liLN) and spleen (SPL) (all n=5). (A) Shown
are the percentages of CD56
brightCD16
+/2 cells positive for each specific receptor within each tissue; *P,.05, **P,.01, ***P,.0001. (B) Shown is the
mean fluorescence intensity (MFI) for each specific receptor expressed by CD56
brightCD16
+/2 cells; *P,.05, **P,.01, ***P,.0001.
doi:10.1371/journal.pone.0030930.g005
Figure 6. Expression of KIR, NKG2A/C, NCR, NKG2D and CD244 within the CD56
dimCD16
+ NK cell subset of committed NK cells in
bone marrow (BM), cord blood (CB), peripheral blood (PB), inguinal LN (inLN), liver LN (liLN) and spleen (SPL) (all n=5). (A) Shown
are the percentages of CD56
dimCD16
+ cells positive for each specific receptor within each tissue; *P,.05, **P,.01. (B) Shown is the mean fluorescence
intensity (MFI) for each specific receptor expressed by CD56
dimCD16
+ cells; *P,.05, **P,.01.
doi:10.1371/journal.pone.0030930.g006
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developed NK cell generation protocols that are being transferred
towards clinical use. Nevertheless, further functional analyses of
developing and committed NK cells within the different NK cell
developmental stages are clearly warranted to support our findings
and to obtain a complete view on the NK cell developmental
pathway that includes the acquisition of the cytolytic and cytokine
producing functions during NK cell development.
Materials and Methods
Tissue collection and mononuclear cell isolation
Bone marrow (BM), peripheral blood (PB), spleen (SPL) and
cord blood (CB) samples were obtained at the Radboud University
Nijmegen Medical Centre (RUNMC; Nijmegen, The Nether-
lands). BM and PB samples were obtained from healthy SCT
donors before mobilization treatment with G-CSF. SPL samples
were obtained from deceased liver or kidney transplantation
donors. CB samples, obtained at birth after normal full-term
delivery, were provided by the cord blood bank of RUNMC. At
the Erasmus Medical Centre (Rotterdam, The Netherlands), liver
draining lymph node (LiLN) samples were obtained from deceased
liver transplantation donors and inguinal lymph node (inLN)
samples from kidney transplant recipients (not treated with
immunosuppressive drugs prior to LN excision). After collection,
each tissue sample was stored at room temperature and processed
within 24 h. LN and SPL samples were first forced through 74 mm
netwell filters (Costar, Corning International, NY, and USA) to
obtain single cell suspensions. Mononuclear cells (MNC) were
isolated by density gradient centrifugation (Lymphoprep; Ny-
comed Pharma, Roskilde, Denmark) and cryopreserved in liquid
nitrogen until further use. At least 5 independent samples of each
tissue were collected. This study was performed in accordance
with the regulations set by the Medical Ethical Committees for
human research of the RUNMC and the Erasmus MC. The
Medical Ethical Committees for human research of the RUNMC
and the Erasmus MC have approved the use of this material for
the current study.
Written informed consent with regard to scientific use was
obtained from all study participants or their representatives.
Multi-color flow cytometry
For analysis, we designed three different 10-color FCM panels
(Table 1) using conjugated mAbs kindly provided by Beckman
Coulter (Marseille, France) with the exception of CD16-FITC
(Dako, Glostrup, Denmark) and CD159c-PE (R&D Systems,
Minneapolis, CA, USA). Combinations of mAb-fluorochromes
were balanced to avoid antibody interactions, sterical hindrance
and to detect also dimly expressing populations. Before multi-color
analyses, all conjugates were titrated and individually tested for
sensitivity, resolution and compensation of spectral overlap.
Isotype controls were used to define marker settings. Thawed
MNC fractions of collected human tissues were assessed on a
Navios
TM flow cytometer and analyzed using Kaluza SoftwareH
Figure 7. Proposed model for human NK cell development in vivo. Based on our data, we propose that precursor NK cells (stage 2) may traffic
from BM to LN, where commitment to the NK cell lineage may take place (stage 3aR3b) followed by potential in situ differentiation of NK cells with
restricted maturation of the NK cell receptor repertoire. For further differentiation of committed NK cells, CD56
dim (stage 3b) or CD56
bright cells (stage
4) may traffic towards splenic tissue in which CD56
dim cells may develop and further maturation of the NK cell receptor repertoire can take place. Final
maturation of NK cells may occur through trafficking of cells towards the periphery from which NK cells may be further distributed to different
compartments in the human body.
doi:10.1371/journal.pone.0030930.g007
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samples were gated on the CD45
+CD3
2 population within
CD45
+/SS gated cells to exclude T cells and endothelial cells
(which may express CD34 but are CD45 negative [37]) and debris
from analysis. To analyze the NK cell receptor repertoire of
committed NK cells, cells were further gated on CD56
+ cells
within the CD45
+CD3
2 population. An additional staining was
performed to check for the presence of lymphoid tissue inducer
cells (LTIs) in the lymphoid tissues [20]. To this end, a surface
staining was performed using CD34-FITC, CD336-PE, CD3-
ECD, CD127-PE-Cy5, CD117-PC7, CD56-APC-A750, CD94-
PB and CD45-PO conjugated mAbs followed by an intracellular
staining of RORct using an APC-conjugated mAb (clone AFKJS-
9; eBioscience, San Diego, CA, USA) together with Fix and Fix/
Perm buffer (eBioscience, San Diego, CA, USA) according to the
manufacturer’s instructions. LTIs were identified within the
CD45
+CD3
2 population as CD34
2CD117
+CD94
2CD56
+/2
cells expressing CD127, NKp44 and RORct.
Cell populations .0.1% of the CD45
+CD3
2 population with a
threshold of more than 50 cells were considered reliable. Cell
populations were considered to be present in a specific tissue when
at least 3 out of 5 samples showed reliable results. Cell populations
that did not suffice to these criteria were excluded from further
(statistical) analysis. An overview of analyzed sample sizes is shown
in Table S1.
Statistical analysis
To compare percentages of cells positive for single markers
between the different tissues, a random effect logistic regression
model was used that accounted for the biological diversity between
samples of each tissue and for the fact that several samples of each
tissue type were taken. Mean fluorescence (MFI) of specific
markers between the different tissues were analyzed using
ANOVA analysis with Tukey post testing. P-values ,0.05 were
considered significant.
Supporting Information
Figure S1 NKG2A expression levels in stages 4, 5a, and
5b in bone marrow (BM), cord blood (CB), peripheral
blood (PB), inguinal LN (inLN), liver LN (liLN) and
spleen (SPL) (all n=5); *P,.05, **P,.01, ***P,.0001.
(TIF)
Figure S2 CD56 and CD16 expression patterns of
committed NK cells (stage 3b-5b) within different
human tissues. BM=bone marrow, CB=cord blood,
PB=peripheral blood, inLN-inguinal LN, liLN=liver LN,
SPL=spleen (all n=5). (A) Shown are representative examples
(one of each tissue) for CD56 and CD16 expression patterns within
the committed NK cell population. (B) Shown are the distribution
of the CD56
brightCD16
+/2 subset (left panel) and the
CD56
dimCD16
+ subset within the different human tissues;
*P,.05, **P,.01, ***P,.0001.
(TIF)
Table S1 To define NK cell developmental stages,
samples were gated on the CD45
+CD3
2 population
within CD45
+/SS gated cells to exclude T cells and
endothelial cells from analysis. For each tissue, the following
items are indicated:
1Total cell number within the CD45
+/SS
gate;
2the amount of cells within the CD45
+CD3
2 gate and;
3the
total amount of cells covering all NK cell developmental stages. All
cell numbers are shown in median (range).
(DOC)
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